ANALYSIS OF THE EFFICIENCY OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION
- Authors: IVANOVA M.R.1, MARZHOKHOVA M.Y.1
-
Affiliations:
- Kh.M. Berbekov Kabardino-Balkar State University
- Issue: No 4 (2013)
- Pages: 50-53
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/276958
- ID: 276958
Cite item
Open Access
Access granted
Abstract
Objective. To analyze treatment results in patients with chronic hepatitis C (CHC) according to the EASL recommendations. Subjects and methods. Fifty-f ive patients aged 21 to 63 years with CHC were followed up. Of them, 11 patients were diagnosed as having Child-Pugh Class A hepatitis C virus-related cirrhosis. Results. The CHC patients were most frequently found to have genotypes 1b (36%) and 3a (36%); genotype 2a was identified in 19% of the patients; CHC genotype was not determined in 9%. The patients with liver cirrhosis showed a preponderance of genotype 3a in 8 cases; genotype 1a was revealed in 3 patients. A sustained virologic response was achieved in only 40% of the patients with genotype 1b, in 80% of those with genotypes 2a and 3a, and in 60% of those with an uncertain genotype. The most common adverse effects of antiviral therapy should include itching and eczema in 23.6% of the patients and varying hematological problems that developed in 74.5% at 9-12 weeks of therapy. Conclusion. It was noted that antiviral therapy was inadequately effective in patients with CHC genotype 1b and the low efficiency of therapy was closely related to significant hepatic fibrosis.
Keywords
Full Text
About the authors
Marina R. IVANOVA
Kh.M. Berbekov Kabardino-Balkar State University
Email: marina19692003@list.ru
Nalchik
M. YU MARZHOKHOVA
Kh.M. Berbekov Kabardino-Balkar State University
Email: madina010@list.ru
Nalchik
References
- Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29: 74-81.
- Yang J.D., Roberts L.R. Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 2010; 7; 448-458.
- Craxi A., Pawlotsky J.M., Wedemeyer H. et al. EASL: Clinical Practice Guidelines: Management of hepatitis С virus infection. European Association for the Study of the Liver. J. Hepatol. 2011; 55: 245-264.
- Jacobson I.M., McHutchison J.G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
- Sherman K.E., Flamm S.L., Afdhal N.H. et al. Telaprevir in combination with peginterferon and ribavirin for 24 or 48 weeks in treatment naive genotype 1 HCV patients who achieved an extended rapid virologic response: final results of phase 3 Illuminate study. Hepatology 2010; 52(Suppl): 401A.
- Zeuzem S., Andreone P., Pol S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
- Bacon B.R., Gordon S.C., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
- Poordad F., McCone J. Jr, Bacon B.R. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
- Awad T., Thorlund K., Hauser G. et al. Proceed with caution peginterferon alpha2a versus peginterferon alfa2b in chronic hepatitis C. A systematic review of randomized trials reply. Hepatology 2010; 52: 2241-2242.
- McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa2b or alfa2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361: 580-593.
Supplementary files
